Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231309 · ClinicalTrials.gov registry record · NA
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
A NA study of Hematologic Malignancies and Hematologic Diseases, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00231309 is a NA study of Hematologic Malignancies and Hematologic Diseases that has completed, run by Emory University. The registered enrollment target is 10 participants, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00231309, a NA study of Hematologic Malignancies and Hematologic Diseases, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to participate in the study. Donors will receive the white cell growth hormone (G-CSF) as a shot (injection) in their arm once a day for three days before they donate their bone marrow cells. Total body irradiation and/or chemotherapy will be given first to prepare the patient's body for the infusion of new bone marrow cells from the donor. Two medicines (cyclosporine and methotrexate) will be used to prevent the new bone marrow cells (graft) from attacking the patient's body (host) (graft-versus-host disease; GVHD). Certain safety checkpoints were built into the study if unwanted/unexpected events were to occur. If the outcomes appear better than could be expected, this will provide a bridge to extend this current approach for other innovative therapies.
Conditions Studied
Interventions
- DRUG Granulocyte Colony Stimulating Factor
Study Locations (1)
Georgia
- Children's Healthcare of Atlanta/Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231309
The ClinicalTrials.gov registry entry for NCT00231309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Granulocyte Colony Stimulating Factor is the first listed.
NCT00231309 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00231309 about?
NCT00231309 is a clinical study titled "Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)". The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to particip...
What is the current status of trial NCT00231309?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2003-07. Estimated completion is 2011-11.
What conditions does trial NCT00231309 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Hematologic Diseases.
What interventions are being tested in trial NCT00231309?
The interventions under investigation include: Granulocyte Colony Stimulating Factor (DRUG).
Who is sponsoring clinical trial NCT00231309?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00231309 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
RECRUITING · NA
-
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
RECRUITING · NA
-
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
COMPLETED · NA
-
IUdR/BUdR Cell Cycle Labelling
COMPLETED · NA
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.